Favorable outcome of gemcitabine-induced acute respiratory distress syndrome;Syndrome de détresse respiratoire aiguë à la gemcitabine d'évolution favorable

Revue de Pneumologie Clinique

Volumn 63, Issue 6, 2007, Pages 379-383

  Bonnichon, A ^a   Vedrine, L ^b   Aletti, M ^b   Le Moulec, S ^b   Borne, M ^b   Margery, J ^a   Bauduceau, O ^b   Fayolle, M ^b   Ceccaldi, B ^b  

^a PERCY MILITARY HOSPITAL   (France)

^b University of Paris Descartes   (France)

Author keywords

Adverse effects; Antimetabolic; ARDS; Gemcitabine; Iatrogenic pneumonitis

Indexed keywords

CISPLATIN; CORTICOSTEROID; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CASE REPORT; HUMAN; LUNG METASTASIS; OUTCOME ASSESSMENT;

EID: 38049150722     PISSN: 07618417     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0761-8417(07)78425-0     Document Type: Article

References (16)

1. Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997;80:286-91.
2. Boiselle PM, Morrin MN, Huberman MS. Gemcitabine pulmonary toxicity: CT features. J Comput Assist Tomogr 2000;24:977-80.
3. Mommens V, Bosquee L, D'Orio V. Pulmonary toxicity due to gemcitabine for NSCLC with brain metastasis. Rev Med Liege 2003;58:123-6.
4. Joerger M, Gunz A, Speich R, Pestalozzi BC. Gemcitabine-related pulmonary toxicity. Swiss Med Wkly 2002;132:17-20.
5. Kouroussis C, Mavroudis D, Kakolyris S, Voloudaki A, Kalbakis K, Souglakos J, et al. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung Cancer 2004;44:363-8.
6. Galleli L, Nardi M, Prantera T, Barbera S, Raffaele M, Arminio D, et al. Retrospective analysis of adverse drug reactions induced by gemcitabine treatment in patients with non-small cell lung cancer. Pharmacoligical Research 2004;49:259-63.
7. Sabria-Tias J, Bonnauf F, Sioniac M. Severe interstitial pneumonitis related to gemcitabine. Rev Mal Respir 2002;19:645-7.
8. Linskens RK, Golding RP, Van Groeningen CJ, Giaccone G. Severe acute lung injury induced by gemcitabine. Neth J Med 2000;56:232-5.
9. Ciotti R, Belotti G, Facchi E, Cantu A, D'Amico A, Gatti C. Sudden pulmonary toxicity following a single infusion of gemcitabine. Ann Oncol 1999;10:997.
10. Maniwa K, Tanaka E, Inoue T, Kato T, Sakuramato M, Minakuchi M, et al. A autopsy case of acute pulmonary toxicity associated with gemcitabine. Intern Med 2003;42:926-7.
11. Barlesi F, Doddoli C, Gimenez C, Greillier L, Lima G, Kleisbauer JP. Toxicité pulmonaire aiguë de la gemcitabine : un rôle pour l'exposition à l'amiante ? Rev Mal Respir 2003;20:201-6.
12. Bredenfeld H, Franklin J, Nogova L, Josting A, Fries S, Mailander V, et al. Severe pulmonary toxicity in patients with advanced-staged Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycine. A report of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2004;22:2424-9.
13. Kudrik FJ, Rivera MP, Molina PL, Maygarden S, Socinski MA. Hypersensivity pneumonitis in advanced non small cell lung cancer patients receiving gemcitabine and paclitaxel: report of two cases and a review of the literature. Clin Lung Cancer 2002;4:52-6.
14. Bégaud B, Evreux JC, Jouglard J, Lagier G. Imputabilité des effets inattendus ou toxiques des médicaments. Thérapie 1985;40:11-8.
15. Ash-Bernal R, Browner I, Erlich R. Early detection and successfull treatment of drug-induced pneumonitis with corticosteroids. Cancer Invest 2002;20:876-9.
16. Stern JB, Caliandro R, Lamer C, Lenoir S, Théodore C, Grunenwald D, et al. Pneumopathie d'hypersensibilité à la gemcitabine s'accompagnant d'insuffisance respiratoire aiguë. Rev Mal Respir 2002;19:253-6.